Use of a glycomics array to establish the anti-carbohydrate antibody repertoire in type 1 diabetes.
Paul M H TranFran DongEileen J KimKatherine P RichardsonLynn K H TranKathleen WaughDiane HopkinsRichard D CummingsPeng George WangMarian J RewersJin-Xiong SheSharad PurohitPublished in: Nature communications (2022)
Type 1 diabetes (T1D) is an autoimmune disease, characterized by the presence of autoantibodies to protein and non-protein antigens. Here we report the identification of specific anti-carbohydrate antibodies (ACAs) that are associated with pathogenesis and progression to T1D. We compare circulatory levels of ACAs against 202 glycans in a cross-sectional cohort of T1D patients (n = 278) and healthy controls (n = 298), as well as in a longitudinal cohort (n = 112). We identify 11 clusters of ACAs associated with glycan function class. Clusters enriched for aminoglycosides, blood group A and B antigens, glycolipids, ganglio-series, and O-linked glycans are associated with progression to T1D. ACAs against gentamicin and its related structures, G418 and sisomicin, are also associated with islet autoimmunity. ACAs improve discrimination of T1D status of individuals over a model with only clinical variables and are potential biomarkers for T1D.
Keyphrases
- type diabetes
- end stage renal disease
- ejection fraction
- glycemic control
- high resolution
- chronic kidney disease
- dendritic cells
- protein protein
- cardiovascular disease
- multiple sclerosis
- systemic lupus erythematosus
- peritoneal dialysis
- insulin resistance
- small molecule
- extracorporeal membrane oxygenation
- patient reported outcomes
- skeletal muscle
- single cell
- celiac disease